(Q44773050)

6 December 2017

title

Factors in antipsychotic drug selection: tolerability considerations (English)

1 reference

6 December 2017

1

Henry A Nasrallah

1 reference

6 December 2017

publication date

1 November 2003

1 reference

6 December 2017

1 reference

6 December 2017

volume

8

1 reference

6 December 2017

issue

11 Suppl 2

1 reference

6 December 2017

page(s)

23-25

1 reference

Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study.

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

Olanzapine-associated diabetes mellitus

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

Prolactin and antipsychotic medications: mechanism of action

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

Clozapine-associated diabetes

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

Motor and mental aspects of acute extrapyramidal syndromes.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

Efficacy of newer generation antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900008166

7 January 2021

10.1017/S1092852900008166

Identifiers

DOI

0 references

1 reference